FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 Instruction 1(b)

1. Name and Address of Reporting Person*  WINSTON ROY  (Last) (First) (Middle)  C/O PACIRA BIOSCIENCES, INC.  5 SYLVAN WAY, SUITE 300					3. E	Issuer Name and Ticker or Trading Symbol     Pacira BioSciences, Inc. [ PCRX ]      Inc. [ PCRX ]      Inc. [ PCRX ]								Relationship of Reporting Person(s) to Issuer Check all applicable)  Director 10% Owner  Officer (give title Other (specify below)  Chief Clinical Officer				
(Street) PARSIPE	PANY N	J tate)	07054 (Zip)		,		nendment, Date of Original Filed (Month/Day/Year)							ndividual or Joint/Group Filing (Check Applicable e)  X Form filed by One Reporting Person Form filed by More than One Reporting Person				n
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)				action	ction 2A. Deemed Execution Date,			3. Transa Code (	ction				5. Amor Securit Benefic Owned	nt of 6. 0 es For (D) Following (I) (		orm: Direct ) or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
Common Stock 06/09/.					/2021		Code	v	7,000	(A) o (D)	r Price	Reporte Transac (Instr. 3	ion(s)		D	(Instr. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	ate, T	4. Transaction Code (Instr. 8)				6. Date Exercisa Expiration Date (Month/Day/Year		•	of Securities		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	tive ties cially l ing ed ction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code		v	(A)	(D)	Date Exercisab		Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$60.96	06/09/2021			A		17,500		(2)	(	06/09/2031	Common Stock	17,500	\$0.00	17,50	0	D	

## **Explanation of Responses:**

- 1. Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2022, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock
- 2. The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

## Remarks:

/s/ Kristen Williams, Attorneyin-Fact

\*\* Signature of Reporting Person Date

06/11/2021

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.